Literature DB >> 21187794

Assessing the impact of migraine onset on work productivity.

Stephen H Landy1, M Chris Runken, Christopher F Bell, Rachel L Higbie, Lisa S Haskins.   

Abstract

OBJECTIVE: Examine the impact of migraine on work productivity, and particularly the association between time of migraine onset and lost productivity as measured by absenteeism and presenteeism.
METHODS: A total of 509 people with migraine completed one online baseline survey and a diary survey after each of their next three migraines. All subjects were 18 or older and employed full time.
RESULTS: Sixty-four percent of migraines occurred on a workday. Of these, 68% resulted in some work productivity impact in the form of absenteeism or presenteeism. Migraines occurring during usual sleeping hours or prior to the start of work had the greatest impact on productivity.
CONCLUSIONS: Findings indicate that absenteeism and presenteeism are both substantial contributors to work productivity loss. Primary factors associated with lost productivity include pain severity, migraine symptoms, and sleep disturbance.

Entities:  

Mesh:

Year:  2011        PMID: 21187794     DOI: 10.1097/JOM.0b013e31812006365

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  10 in total

1.  Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study.

Authors:  Elizabeth K Seng; Matthew S Robbins; Robert A Nicholson
Journal:  Cephalalgia       Date:  2016-08-03       Impact factor: 6.292

2.  Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey.

Authors:  A Brett Hauber; Brennan Mange; Mark A Price; Daniel Wolin; Mark Bensink; James A Kaye; David Chandler
Journal:  Support Care Cancer       Date:  2017-08-07       Impact factor: 3.603

3.  Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.

Authors:  Theodoros V Giannouchos; Dimos-Dimitrios Mitsikostas; Robert L Ohsfeldt; Athanassios Vozikis; Paraskevi Koufopoulou
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

4.  Difficulties in work activities and the pervasive effect over disability in patients with episodic and chronic migraine.

Authors:  D D'Amico; L Grazzi; M Curone; P Di Fiore; A Proietti Cecchini; M Leonardi; C Scaratti; A Raggi
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

5.  Antimigraine medication use and associated health care costs in employed patients.

Authors:  Jun Wu; Mary D Hughes; Matthew F Hudson; Peggy J Wagner
Journal:  J Headache Pain       Date:  2011-11-30       Impact factor: 7.277

6.  Interventions for migraine prophylaxis: protocol of an umbrella systematic review and network meta-analysis.

Authors:  Hui Zheng; Min Chen; Dequan Huang; Juan Li; Qin Chen; Jianqiao Fang
Journal:  BMJ Open       Date:  2015-05-06       Impact factor: 2.692

7.  Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.

Authors:  Richard B Lipton; Sagar Munjal; Dawn C Buse; Aftab Alam; Kristina M Fanning; Michael L Reed; Todd J Schwedt; David W Dodick
Journal:  Headache       Date:  2019-08-13       Impact factor: 5.887

8.  Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials.

Authors:  Pei-Wen Chi; Kun-Yi Hsieh; Kuan-Yu Chen; Chin-Wang Hsu; Chyi-Huey Bai; Chiehfeng Chen; Yuan-Pin Hsu
Journal:  PLoS One       Date:  2019-10-23       Impact factor: 3.240

9.  Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire.

Authors:  Alberto Raggi; Venusia Covelli; Erika Guastafierro; Matilde Leonardi; Chiara Scaratti; Licia Grazzi; Marco Bartolini; Giovanna Viticchi; Sabina Cevoli; Giulia Pierangeli; Gioacchino Tedeschi; Antonio Russo; Piero Barbanti; Cinzia Aurilia; Carlo Lovati; Luca Giani; Fabio Frediani; Paola Di Fiore; Francesco Bono; Laura Rapisarda; Domenico D'Amico
Journal:  J Headache Pain       Date:  2018-09-10       Impact factor: 7.277

10.  Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.

Authors:  Evan Popoff; Karissa Johnston; Robert Croop; Alexandra Thiry; Linda Harris; Lauren Powell; Vladimir Coric; Gilbert L'Italien; James Moren
Journal:  Headache       Date:  2021-05-22       Impact factor: 5.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.